Biogen Reports Q3 2026 Financial Results
Biogen reported third-quarter 2026 adjusted earnings per share of $2.62, exceeding the FactSet consensus estimate of $1.99, and revenue of $2.80 billion, surpassing the expected $2.63 billion.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — BIOGEN INC. (BIIB)
Filed: 2026-10-28 AccNo: 0000875045-26-000094 Size: 802 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Which Biotech ETF Is the Better Buy: VanEck’s BBH or Invesco’s Factor-Driven PBE?
VanEck Biotech ETF (BBH) offers lower costs (0.35% expense ratio) and concentrated exposure to 25 large-cap biotech leaders, outperforming Invesco Biotechnology & Genome ETF (PBE) over the past year. However, PBE delivers higher dividend income (1.3% yield) and slightly better five-year returns through a multifactor selection strategy. BBH is ideal for cost-conscious momentum investors, while PBE suits those seeking income and a diversified factor-driven approach.